Director's Dealings

RNS Number : 7664T

hVIVO plc

05 July 2018

 

hVIVO PLC

("hVIVO" or the "Company")

 

Director's Dealings

London, UK, 5 July 2018: hVIVO plc (AIM: HVO), announces that application has been made to AIM for the admission of 7,477 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").

The New Ordinary Shares have been allotted pursuant to the purchase by Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of his letter of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Ellertson and Mr Winschel had entered into binding commitments to purchase $20,000 and £4,000 of hVIVO plc new ordinary shares respectively per quarter.  Jaime Ellertson waived his Non-Executive Directors Fee with effect from 1 April 2018 and accordingly at the same time discontinued his quarterly purchase of shares, which was 40% of his fee.

The New Ordinary Shares represent Mr Winschel's investment for the quarter ended 30 June 2018.  On 5 July 2018, Mr Winschel invested in an additional 7,477 ordinary shares, at a price of 53.5 pence per share.

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 78,223,614 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 11 July 2018.  Following Admission, Mr Winschel will be interested in a total of 73,138 ordinary shares of 5.0p in the Company, representing less than 0.1% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the persons discharging managerial responsibilities/persons closely associated
a)	Name	Jim Winschel
2	Reason for the notification
a)	Position/ status	Non-Executive Director
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 5 pence each  GB00B6ZM0X53
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Director Price (p) Volume Jim Winschel 53.5 7,477
e)	Aggregated information - Aggregated volume - Price - Aggregated total	7,477 53.5p £4,000.20
f)	Date of the transaction	5 July 2018
g)	Place of the transaction	London Stock Exchange, AIM

For further information please contact:

hVIVO plc
Trevor Phillips (Executive Chairman)	[phone]
Fleur Wood (Director, Investor Relations)
Numis Securities Limited	[phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell	[phone]

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.

 

END

 

 

DSHUGUWAMUPRGWA